Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of today’s top gainers. The company’s shares have moved 30.62% on the day to $14.22.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases.
So far today, approximately 125.86M shares of Amicus Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.94M shares.
Amicus Therapeutics, Inc. share prices have moved between a 52-week high of $14.36 and a 52-week low of $5.51. The stock has moved 3.27% over the past week.
To learn more, visit Amicus Therapeutics, Inc.
Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected
About IBN
IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]